Broadview’s mission is to accelerate the development of promising technology for the diagnosis and treatment of cardiovascular and neurovascular disease through targeted investments.
The mission and structure of Broadview Ventures can be traced to the Leducq Foundation and its supporting trust, created in 1996 by French entrepreneur and industrialist Jean Leducq, together with his wife Sylviane. Motivated by a multi-generational family history of cardiovascular illness, and inspired to work at the international level through years of living and working abroad, the Leducqs used the proceeds of the sale of the family’s multinational linen and uniform services businesses to establish a foundation for cardiovascular research with a mission to improve human health through international efforts to combat cardiovascular and neurovascular disease. The foundation’s signature program, the Transatlantic Networks of Excellence in Cardiovascular and Neurovascular Disease, supports international networks of experts in cardiovascular disease and stroke that work collaboratively to advance scientific knowledge, bring new technology to patient care, and to help to train early career investigators. Since making its first award in 1999, the foundation has committed over $350 million to cardiovascular and neurovascular research, supporting 47 research networks at 130 institutions in 19 countries.
From the outset the Leducq organization was interested in promoting the technology that was developed through the research it supported. The board of the Leducq Foundation Trust soon determined that the best way to accomplish this objective was to create an independent organization dedicated solely to promoting and investing in technology. In 2008, it decided to create Broadview Ventures, specifically addressing the translational gap by providing seed and early stage funding for companies on the path to developing commercial products for patients with cardiovascular and neurovascular disease. Broadview shares a mission in cardiovascular and neurovascular disease with the Fondation Leducq, but proceeds through a direct investment model while the foundation works through a more traditional grant program.
Our primary investment goal is to improve human health in the areas of cardiovascular disease and stroke.
Indication – Broadview invests in cardiovascular, metabolic, and neurovascular disease
- We define cardiovascular broadly to include:
- Heart Disease
- Peripheral Vascular Disease
- Valvular Disorders
- Hypertension and Cardio-Renal
- Underlying pathways (e.g., inflammation, atherogenesis)
- We are interested in metabolic disease as it relates to cardiovascular risk factors, including:
- Type II diabetes
- Metabolic syndrome
- Stroke is the primary indication within the neurovascular focus
Technology – diversified across therapeutics, devices, diagnostics, and regenerative therapies
Stage – our preferred stage of investment is Seed to Series A, typically late pre-clinical through clinical proof-of-concept
Broadview Ventures reviews investment opportunities on a rolling basis. To be considered, please send an executive summary of your company or technology to email@example.com. We will respond in 7-10 business days.